BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
- Conditions
- Urinary Bladder NeoplasmsMuscle-Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 855
- Registration Number
- NCT03661320
- Locations
- 🇯🇵
Local Institution - 0171, Kita-gun, Kagawa, Japan
🇯🇵Local Institution - 0176, Hidaka-shi, Saitama, Japan
🇯🇵Local Institution - 0172, Shinjuku-ku, Tokyo, Japan
An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 131
- Registration Number
- NCT03660436
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03660072
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 139
- Registration Number
- NCT03656718
- Locations
- 🇺🇸
Local Institution - 0012, Eugene, Oregon, United States
🇺🇸Greenville Health System, Greenville, South Carolina, United States
🇺🇸Local Institution - 0011, Tyler, Texas, United States
Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells
- Conditions
- Cancer
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2018-08-23
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1056
- Registration Number
- NCT03644498
- Locations
- 🇺🇸
Local Institution, Princeton, New Jersey, United States
An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 50
- Registration Number
- NCT03634969
- Locations
- 🇺🇸
Prism Research, Saint Paul, Minnesota, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 118
- Registration Number
- NCT03634995
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸PRA Health Science KK, Lenexa, Kansas, United States
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 783
- Registration Number
- NCT03635983
- Locations
- 🇺🇸
Local Institution - 0187, Tucson, Arizona, United States
🇺🇸Local Institution - 0001, Houston, Texas, United States
🇺🇸Local Institution - 0064, Fairfax, Virginia, United States
Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 666
- Registration Number
- NCT03624127
- Locations
- 🇺🇸
Keck School of Medicine, Los Angeles, California, United States
🇯🇵Sapporo Skin Clinic, Sapporo, Hokkaido, Japan
🇵🇱DermoDent - Centrum Medyczne Czajkowscy, Osielsko, Poland
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1020
- Registration Number
- NCT03611751
- Locations
- 🇺🇸
Interspond - Savin Medical Group, Miami Lakes, Florida, United States
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States